Astellas Pharma Inc. is equally embarking on several ambitious ventures, with collaborative research agreements, and many therapeutics gaining international approval. They've made a significant
$2.2bn gene therapy deal with AviadoBio Ltd. This trend continued with research collaboration license agreement in oncology with Poseida Therapeutics. Another
innovative collaboration was between Astellas and the Graduate School of Medicine / Faculty of Medicine, Osaka University, to develop pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapies. Remarkably, Astellas collaborated with YASKAWA to create a unique
cell therapy ecosystem by combining pharmaceutical and robotics technologies. An innovative digital campaign was initiated, proving valuable for patients. A
new digital solution for heart failure patients is on the horizon, while the FDA has approved the company's digital health solution. In another decisive step, the European Commission and Japan approved several of Astellas' therapeutics. The company completed the acquisition of Propella Therapeutics and aims to establish a centre in the US to accelerate the discovery of breakthrough therapies. Despite major achievements, the company experienced a setback when the US FDA declined to approve Astellas' gastric cancer drug.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Thu, 10 Oct 2024 18:22:24 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor 6
